Skip to content

Thursday | January 29, 2026 | Dhaka

Nine dengue patients die in 24 hrs

Published · Updated

Children are playing inside mosquito net as cases of dengue infections have been on the rise, particularly in the capital. This photo was taken on Saturday.

Staff Reporter :
Nine more deaths were reported from dengue in 24 hours till Saturday morning, raising the fatalities from the mosquito-borne disease in Bangladesh to 537 this year.

As per the data from the Directorate General of Health Services (DGHS), 1,960 more dengue patients were hospitalised with the viral fever during the period.

Among the new patients, 833 were admitted to hospitals in Dhaka and the rest outside the capital – indicating a worsening situation across the country, according to DGHS.

A total of 8,232 dengue patients, including 3,846 in the capital, are now receiving treatment at hospitals across the country.
So far, the DGHS has recorded 1,12,184 dengue cases and 1,03,411 recoveries this year.

In these situations, the UN World Health Organisation urged swift action as dengue cases surge in Bangladesh.

‘The higher incidence of dengue is taking place in the context of an unusual episodic amount of rainfall, combined with high temperatures and high humidity, which have resulted in an increased mosquito population throughout Bangladesh,’ WHO said.

Apart from these, Dhaka South City Corporation (DSCC) Mayor Barrister Sheikh Fazle Noor Taposh on Saturday said the city corporation has intensified its efforts to combat the dengue outbreak as the mosquito-borne disease has already gripped the country.

Meanwhile, vaccine manufacturer Indian Immunologicals Limited (IIL) expects to commercially launch its dengue fever vaccine by early 2026.

A top executive of this company said, as the race to develop the country’s first such vaccine heats up.

IIL’s managing director, K.Anand Kumar, said the dengue vaccine’s early-stage trials conducted on about 90 individuals, aged 18-50 years, did not demonstrate any adverse effects.

“We’re about to complete Phase 1 trials and will proceed to the next level.

All of this will take at least two to three years. So, we are looking at January 2026 for the vaccine’s commercial launch,” Kumar said.

The early-stage trials are about determining the safety factor and efficacy to a small extent, Kumar said.

U.S.-based National Institute of Health (NIH) has provided IIL with the virus required for developing the vaccine, Kumar added.